Glen­mark, Al­pham­ab deal worth up to $700M; Tour­ma­line’s $150M of­fer­ing; Re­pare records $40M mile­stone

Plus, news about Ve­ra Ther­a­peu­tics and Cel­lec­tar Bio­sciences:

Al­pham­ab On­col­o­gy, Glen­mark ink li­cens­ing deal: Per the agree­ment, Glen­mark will spend up to $700.8 mil­lion in up­front and mile­stone pay­ments to de­vel­op and com­mer­cial­ize Al­pham­ab’s PD-LI in sev­er­al re­gions, in­clud­ing In­dia and the Mid­dle East. — Jaimy Lee

Tour­ma­line Bio’s $150M of­fer­ing: The biotech is sell­ing about 4.6 mil­lion shares, at $32.50 each. Back in June, Tour­ma­line’s re­verse merg­er with Ta­laris Ther­a­peu­tics put the com­pa­ny on the Nas­daq. It’s plan­ning to put its sub­cu­ta­neous TOUR006, which goes af­ter in­ter­leukin-6, in­to a piv­otal tri­al for thy­roid eye dis­ease this year. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER